Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          Enter the terms you wish to search for.
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations                  
Office of the Assistant Secretary for Health
  About OASH
    
                        
                                            
      
      
      Public Health Offices
    
                        
                                            
      
      
      Advisory Committees

              

    



Breadcrumb
    HHS
                              ASH Home
                              Office of Science and Medicine
                              InnovationX
                              Vector-Borne Disease National Strategy
                              The Kay Hagan Tick Act


    

    

    Navigate to:
  Office of Science and Medicine
    
                                                  
                                                                  
            
      
      
      
      Chief Medical Officer
                                            
            
            Initiative on Substance Exposure in the Mother-Infant Dyad
    
                                                  
                                                                                        
                          
      
      
      
      InnovationX
                                            
            
            Covid-19 Data Driven Innovation
    
                                                                
                                                                  
            
      
      
      
      Human-Centered Design
                          
            
            Clinical Response through Emerging Technology (CRET)
    
                                                  
                                            
            
      
      
      
      Sickle Cell Disease
    
                                                  
                                            
            
      
      
      
      KidneyX
    
                                                                
                                                                  
            
      
      
      
      Lyme Innovation
                          
            
            Lyme Innovation: Real-World Impact
    
                                                  
                                            
            
      
      
      
      LymeX
    
                                                  
                                            
            
      
      
      
      PandemicX
    
                                                                
                                                                                        
                          
      
      
      
      Vector-Borne Disease National Strategy
                          
            
            Public Engagement
    
                                                  
                                                                  
                          
      
      
      
      The Kay Hagan Tick Act
    
                                    
                                            
            
      
      
      
      LeadershipText resize icon

                    




The Kay Hagan Tick Act








  
  
    

  
      





As mandated by the Kay Hagan Tick Act, signed into law in 2019 as part of the FY 2020 Further Consolidated Appropriations Act - PDF, OASH is working closely with CDC to develop a National Strategy to address Vector-Borne Diseases carried by ticks and other blood-feeding vectors.

**Sec. 404. KAY HAGAN TICK ACT.**

SHORT TITLE.—This section may be cited as the “Kay Hagan Tick Act”.
	COMBATING VECTOR-BORNE DISEASES.— Title III of the Public Health Service Act is amended by inserting after section 317T (42 U.S.C. 247b–22) the following:**“SEC. 317U. NATIONAL STRATEGY AND REGIONAL CENTERS OF EXCELLENCE IN VECTOR-BORNE DISEASES.**
	IN GENERAL.—The Secretary shall—
		A. ensure the development and implementation of a national strategy to address vector-borne diseases, including tick-borne diseases, that—
			identifies and assesses gaps and any unnecessary duplication in federally-funded programs; and
				identifies strategic goals to address such diseases and appropriate benchmarks to measure progress toward achievingsuch goals; and
				B. update such strategy, as appropriate; and
			coordinate programs and activities, including related to data collection, research, and the development of diagnostics, treatments, vaccines, and other related activities, to address vector-borne diseases, including tick-borne diseases, across the Department of Health and Human Services and with other Federal agencies or departments, as appropriate.
		Consultation.—In carrying out subsection (a)(1), the Secretary shall consult with the Tick-Borne Disease Working Group established under section 2062 of the 21st Century Cures Act (42 U.S.C. 284s) and other individuals, as appropriate, such as—
		epidemiologists with experience in vector-borne diseases;
			representatives of patient advocacy and research organizations that focus on vector-borne diseases, including such organizations that have demonstrated experience in related research, public health, data collection, or patient access to care;
			health information technology experts or other information management specialists;
			clinicians, entomologists, vector management professionals, public health professionals, and others with expertise in vector-borne diseases; and
			researchers, including researchers with experience conducting translational research.
		Centers of Excellence.—The Secretary, in coordination with the Director of the Centers for Disease Control and Prevention, shall award grants, contracts, or cooperative agreements to institutions of higher education for the establishment or continued support of regional centers of excellence in vector-borne diseases to address vector-borne diseases, including tick-borne diseases, by—
		facilitating collaboration between academia and public health organizations for public health surveillance, prevention, and response activities related to vector-borne diseases, including tick-borne diseases;
			providing training for public health entomologists and other health care professionals, as appropriate, to address vector-borne diseases, including tick-borne diseases;
			conducting research to develop and validate prevention and control tools and methods, including evidence-based and innovative, evidence-informed tools and methods to anticipate and respond to disease outbreaks; or
			preparing for and responding to outbreaks of vector-borne diseases, including tick-borne diseases.
		Eligibility.—To be eligible to receive a grant, contract, or cooperative agreement under subsection (c), an entity shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require, including a description of how the entity will conduct the activities described in such subsection.
		Reports.—
		Program Summary.—An entity receiving an award under subsection (c) shall, not later than one year after receiving such award, and annually thereafter, submit to the Secretary a summary of programs and activities funded under the award.
			Progress Report.—Not later than 4 years after the date of enactment of this section, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report on the progress made in addressing vector-borne diseases, including tick-borne diseases, through activities carried out under this section.
		Authorizations of Appropriations.—For the purpose of carrying out this section, there are authorized to be appropriated $10,000,000 for each of fiscal years 2021 through 2025.”.
		ENHANCING CAPACITY TO ADDRESS VECTOR-BORNE DISEASES.—Subtitle C of title XXVIII of the Public Health Service Act (42 U.S.C. 300hh-31 et seq.) is amended by adding at the end the following:**“SEC. 2822. ENHANCED SUPPORT TO ASSIST HEALTH DEPARTMENTS IN ADDRESSING VECTOR-BORNE DISEASES.”**
		In General.—The Secretary acting through the Director of the Centers for Disease Control and Prevention, may enter into cooperative agreements with health departments of States, political subdivisions of States, and Indian Tribes and Tribal organizations in areas at high risk of vector-borne diseases in order to increase capacity to identify, report, prevent, and respond to such diseases and related outbreaks.
		Eligibility.—To be eligible to enter into a cooperative agreement under this section, an entity described in subsection (a) shall prepare and submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require, including a plan that describes—
		How the applicant proposes to develop or expand programs to address vector-borne disease risks, including through—
			related training and workforce development;
				programmatic efforts to improve capacity to identify, report, prevent, and respond to such disease and related outbreaks; and
				other relevant activities identified by the Director of the Centers for Disease Control and Prevention, as appropriate;
			the manner in which the applicant will coordinate with other Federal, Tribal, and State agencies and programs, as applicable, related to vector-borne diseases, as well as other relevant public and private organizations or agencies; and
			the manner in which the applicant will evaluate the effectiveness of any program carried out under the cooperative agreement.
		AUTHORIZATION OF APPROPRIATIONS.—For the purposes of carrying out this section, there are authorized to be appropriated $20,000,000 for each of fiscal years 2021 through 2025.”.

                    
  


Content created by Assistant Secretary for Health (ASH) Content last reviewed August 27, 2023Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​